scholarly journals miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2

Oncotarget ◽  
2018 ◽  
Vol 9 (53) ◽  
pp. 30053-30065 ◽  
Author(s):  
Zeinab Mohamed ◽  
Mohamed Kamel Hassan ◽  
Safwat Okasha ◽  
Takashi Mitamura ◽  
Sarah Keshk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hippo Pathway ◽  
Taxane Resistance ◽  
The Hippo Pathway

scholarly journals Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Sandra Muñoz-Galván ◽  
Blanca Felipe-Abrio ◽  
Eva M. Verdugo-Sivianes ◽  
Marco Perez ◽  
Manuel P. Jiménez-García ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Molecular Mechanisms ◽  
Target Genes ◽  
Hippo Pathway ◽  
Ovarian Tumors ◽  
Tumor Resistance ◽  
Functional Link ◽  
The Hippo Pathway

Abstract Background Ovarian cancer is one of the most common and malignant cancers, partly due to its late diagnosis and high recurrence. Chemotherapy resistance has been linked to poor prognosis and is believed to be linked to the cancer stem cell (CSC) pool. Therefore, elucidating the molecular mechanisms mediating therapy resistance is essential to finding new targets for therapy-resistant tumors. Methods shRNA depletion of MYPT1 in ovarian cancer cell lines, miRNA overexpression, RT-qPCR analysis, patient tumor samples, cell line- and tumorsphere-derived xenografts, in vitro and in vivo treatments, analysis of data from ovarian tumors in public transcriptomic patient databases and in-house patient cohorts. Results We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy. Similarly, overexpression of miR-30b targeting MYPT1 results in enhanced CSC-like properties in ovarian tumor cells and is connected to the activation of the Hippo pathway. Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo. Conclusions Our work provides a functional link between the resistance to chemotherapy in ovarian tumors and the increase in the CSC pool that results from the activation of the Hippo pathway target genes upon MYPT1 downregulation. Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.

571: The Hippo pathway gene, YAP, is an oncogene in ovarian cancer

2014 ◽  
Vol 50 ◽  
pp. S137
Author(s):  
X. Zhang ◽  
J. George ◽  
S. Deb ◽  
J.L. Degoutin ◽  
E.A. Takano ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hippo Pathway ◽  
Pathway Gene ◽  
The Hippo Pathway

scholarly journals The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene

Oncogene ◽  
2011 ◽  
Vol 30 (25) ◽  
pp. 2810-2822 ◽  
Author(s):  
X Zhang ◽  
◽  
J George ◽  
S Deb ◽  
J L Degoutin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hippo Pathway ◽  
The Hippo Pathway
Sign in / Sign up

Export Citation Format

Share Document